Human Anti-HIV-1 Recombinant Antibody (clone VRC26.25) (CAT#: PABL-140)

Recombinant Human Antibody (VRC26.25) is capable of binding to HIV-1, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody neutralized 57% of diverse clade 43 viral isolates and 70% of clade C isolates with remarkable potency.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Neutralization profiles of PGDM1400 and CAP256-VRC26.25 against a multi-clade panels of 208 pseudoviruses (A) and highlighting specifically the activity of both bNAbs against clade C pseudoviruses (B).

Figure 1 Neutralization profiles of PGDM1400 and CAP256-VRC26.25 against a multi-clade panels of 208 pseudoviruses (A) and highlighting specifically the activity of both bNAbs against clade C pseudoviruses (B).

(A) Each bar represents the IC80 (μg/ml) of PGDM1400 (upper graph) or CAP256-VRC26.25 (lower graph) against a single virus. Viruses are ranked according to increasing IC80 values. Bars reaching the dotted line represent IC80 values>50 μg/mL. The red bars highlight the IC80 values for PGDM1400 (upper graph) or CAP256-VRC26.25 (lower graph) against SHIV-325c. (B) IC80 values for PGDM1400 and CAP256-VRC26.25 against SHIV-325c (red dot) and against the clade C pseudoviruses included in panel (A). The horizontal bars represent the mean of IC80 values of neutralizable pseudoviruses.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.

Figure 2 Neutralization of SHIV-325c by CAP256-VRC26.25, PGDM1400 and PG9

Figure 2 Neutralization of SHIV-325c by CAP256-VRC26.25, PGDM1400 and PG9

Neutralization was measured using replication competent challenge stock SHIV-325c infection of TZM-bl cells. All 3 antibodies showed 100% neutralization of SHIV-325c with no evidence of a plateau effect below 100% neutralization.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.

Figure 3 Protective efficacy of PGDM1400 and CAP256-VRC26.25-LS against SHIV-325c in rhesus macaques

Figure 3 Protective efficacy of PGDM1400 and CAP256-VRC26.25-LS against SHIV-325c in rhesus macaques

Plasma viral RNA (log RNA copies/mL) are shown for animals that received placebo control (A), 2 mg/kg PGDM1400 (B), 0.4 mg/kg PGDM1400 (C), 0.08 mg/kg PGDM1400 (D), 2 mg/kg CAP256-VRC26.25-LS (E), 0.4 mg/kg CAP256-VRC26.25-LS (F), or 0.08 mg/kg CAP256-VRC26.25-LS (G). All placebo controls became infected. Protection was observed in all animals that received CAP256-VRC26.25-LS at all doses. 1/5 animals in the PGDM1400 2 mg/kg dose group and 3/4 animals in the 0.08 mg/kg PGDM1400 dose group were infected. The assay sensitivity limit was>50 RNA copies/mL.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.

Figure 4 Serum concentration of CAP256-VRC26.25-LS and PGDM1400 in antibody treated animals

Figure 4 Serum concentration of CAP256-VRC26.25-LS and PGDM1400 in antibody treated animals

bNAb concentrations were determined by ELISA. The results show average serum concentrations of 19.8 μg/ml, 3.3 μg/ml and 0.75 μg/mL on the day of challenge in the CAP256-VRC26.25-LS 2 mg/kg, 0.4 mg/kg and 0.08 mg/kg groups, respectively, and 6.9 μg/mL, 2.5 μg/mL and 0.22 μg/mL on the day of challenge in the PGDM1400 2 mg/kg, 0.4 mg/kg and 0.08 mg/kg groups, respectively.

Julg, B., Tartaglia, L. J., Keele, B. F., Wagh, K., Pegu, A., Sok, D.,... & Joyce, M. G. (2017). Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science translational medicine, 9(406), eaal1321.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Type
  • Human IgG1
  • Specificity
  • Tested positive against HIV-1 HIV-1
  • Species Reactivity
  • HIV-1
  • Clone
  • VRC26.25
  • Applications
  • WB, ELISA, Neut, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • Neutralization of diverse, replication-competent SHIV challenge stocks (including SHIV-325c) or Env-pseudoviruses was evaluated in vitro by using TZM-bl target cells and a luciferase reporter assay. Briefly, HIV-1 Env pseudoviruses were generated by transfection in 293T cells, and SHIV challenge stocks were produced by transfection of 293T cells with infectious molecular clone plasmids, followed by propagation in human or rhesus PBMC. The rhesus PBMC derived stock of SHIV-AD8 was kindly provided by Dr. Malcolm Martin and SHIV-1157ipd3N4 was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Ruth Ruprecht. SHIV stocks or HIV-1 pseudoviruses were incubated with the antibody for 30 min at 37°C before TZM-bl cells were added. The protease inhibitor indinavir was added to assays with SHIV stocks to a final concentration of 1 μM to limit infection of target cells to a single round of viral replication. Luciferase expression was quantified 48 h after infection upon cell lysis and the addition of luciferin substrate (Promega).

Target

  • Alternative Names
  • HIV-1; human immunodeficiency virus

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone VRC26.25"

See other products for "HIV-1"

Single-domain Antibody

CAT Product Name Application Type
NAB-1889-sdAb Recombinant Anti-HIV-1 VHH Single Domain Antibody WB, ICC, ChiP, FA, ELISA Llama VHH
PNBL-038 Recombinant Anti-HIV-1 C186 gp120 VHH Single Domain Antibody (A12) WB, FuncS Llama VHH

Humanized Antibody

Immunotoxin

CAT Product Name Application Type
AGTO-G037E Anti-HIV-1 immunotoxin 3B3 (scFv)-PE Cytotoxicity assay, Function study
AGTO-G037D Anti-HIV-1 immunotoxin 3B3 (scFv)-DT Cytotoxicity assay, Function study

Chimeric Antibody

CAT Product Name Application Type
PABX-093-S (P) Recombinant Mouse Anti-HIV-1 Antibody scFv Fragment (Fab28) WB, ELISA, FuncS scFv

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-4221 Rabbit Anti-HIV-1 Recombinant Antibody (clone SI300DS) ELISA, ICC, IF, FC Rabbit IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-068 Afuco™ Anti-HIV-1 ADCC Recombinant Antibody (Suvizumab), ADCC Enhanced ELISA, IP, FC, FuncS, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-140. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare